• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients.

作者信息

Terra Rafik, Thiant Stéphanie, Claveau Jean-Sébastien, Roy Jean, Ahmad Imran, LeBlanc Richard

机构信息

Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.

Hematology-Oncology and Cell Therapy Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Montréal, QC, Canada.

出版信息

Bone Marrow Transplant. 2025 May 17. doi: 10.1038/s41409-025-02626-x.

DOI:10.1038/s41409-025-02626-x
PMID:40379906
Abstract
摘要

相似文献

1
Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients.新诊断骨髓瘤患者接受序贯自体/异基因移植后可测量残留病的预后价值及动力学模式
Bone Marrow Transplant. 2025 May 17. doi: 10.1038/s41409-025-02626-x.
2
MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma.对于新诊断的适合移植的多发性骨髓瘤患者，MASS-4比MASS-3更适合用于预后分层。
Ann Med. 2025 Dec;57(1):2519671. doi: 10.1080/07853890.2025.2519671. Epub 2025 Jul 1.
3
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.新诊断骨髓瘤中可测量残留病指导的治疗
N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3.
4
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.自体干细胞移植联合治疗对伴有髓外疾病和高危细胞遗传学的新诊断多发性骨髓瘤的疗效改善：来自欧洲血液和骨髓移植学会慢性恶性肿瘤工作组的研究。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6.
5
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.优化多发性骨髓瘤的自体干细胞移植：强化化疗动员的影响
Transplant Cell Ther. 2024 Aug;30(8):774.e1-774.e12. doi: 10.1016/j.jtct.2024.05.016. Epub 2024 May 18.
6
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.isatuximab、硼替佐米、来那度胺与小剂量地塞米松用于不适宜移植的多发性骨髓瘤患者（REST）：一项多中心、单臂、2期试验
Lancet Haematol. 2025 Feb;12(2):e120-e127. doi: 10.1016/S2352-3026(24)00347-8.
7
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.新诊断的伴有17p缺失的多发性骨髓瘤患者接受一线自体造血干细胞移植的真实世界结果
Transplant Cell Ther. 2025 Jan;31(1):12.e1-12.e10. doi: 10.1016/j.jtct.2024.10.011. Epub 2024 Oct 22.
8
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合双次移植治疗高危初诊多发性骨髓瘤。
Blood. 2024 May 16;143(20):2029-2036. doi: 10.1182/blood.2023023597.
9
Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).年轻供者年龄和 upfront tandem 是接受 tandem 自体-异基因干细胞移植治疗的多发性骨髓瘤患者生存的两个独立预后因素：来自法国骨髓和细胞治疗协会（SFGM-TC）的回顾性研究。
Haematologica. 2012 Apr;97(4):482-90. doi: 10.3324/haematol.2011.049742. Epub 2011 Nov 4.
10
Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.新诊断的多发性骨髓瘤患者接受串联自体同源干细胞移植治疗与仅接受自体移植的患者相比，总体生存更好，复发时的结果相似。
Clin Transplant. 2020 Dec;34(12):e14099. doi: 10.1111/ctr.14099. Epub 2020 Oct 22.

本文引用的文献

1
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.TOURMALINE-MM3 和-MM4 试验中 1280 例骨髓瘤患者维持治疗期间微小残留病灶动态变化与预后改善的关系。
Blood. 2023 Feb 9;141(6):579-591. doi: 10.1182/blood.2022016782.
2
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
3
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
来那度胺持续维持治疗的多发性骨髓瘤患者微小残留病动态变化：一项单臂、单中心2期试验
Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7.
4
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.自体-异体造血干细胞移植序贯治疗多发性骨髓瘤的长期随访。
Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.
5
Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma.纵向流式细胞术鉴定“微小残留病”（MRD）演变模式，以预测适合移植的多发性骨髓瘤患者的预后。
Biol Blood Marrow Transplant. 2018 Dec;24(12):2568-2574. doi: 10.1016/j.bbmt.2018.07.040. Epub 2018 Aug 22.
6
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.骨髓瘤患者移植或来那度胺巩固治疗后的微小残留病：一项前瞻性分析。
Oncotarget. 2017 Jan 24;8(4):5924-5935. doi: 10.18632/oncotarget.12641.
7
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
8
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.多发性骨髓瘤的异基因造血细胞移植：疾病风险和移植后微小残留病对生存的影响。
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86. doi: 10.1016/j.clml.2016.03.001. Epub 2016 Mar 30.